Literature DB >> 3155990

Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.

J E Talmadge, J Adams, H Phillips, M Collins, B Lenz, M Schneider, E Schlick, R Ruffmann, R H Wiltrout, M A Chirigos.   

Abstract

In this report, we describe the immunomodulatory characteristics of poly(I,C)-LC, a synthetic, double-stranded nucleic acid polymer, polyinosinic-polycytidylic acid, that is complexed with poly-L-lysine and solubilized by the addition of carboxymethylcellulose. We consistently observed, both in vitro and in vivo, stimulation of macrophage cytotoxicity and augmentation of natural killer-cell activity by poly(I,C)-LC. This immunomodulator also increased the allogeneic mixed-lymphocyte response, without any blastogenic effect on responder cells cultured in the absence of allogeneic stimulator cells. Further, the addition of poly(I,C)-LC to an allogeneic mixed-lymphocyte tumor reaction did not stimulate the development of cytotoxic effector T-cells. Poly(I,C)-LC did, however, have adjuvant activity when admixed with irradiated tumor cells in the immunization of syngeneic mice. Unlike classic adjuvants, poly(I,C)-LC also enhanced the development of specific cytotoxic T-lymphocytes when it was injected either i.v. or i.p. in conjunction with a vaccine delivered at an intradermal site. The results indicate that poly(I,C)-LC has considerable potential as an immunotherapeutic agent, with the ability not only to induce macrophage and NK cell activation but also to stimulate specific cytotoxic T-lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155990

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.

Authors:  Hiroaki Shime; Misako Matsumoto; Hiroyuki Oshiumi; Shinya Tanaka; Akio Nakane; Yoichiro Iwakura; Hideaki Tahara; Norimitsu Inoue; Tsukasa Seya
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

2.  Immunomodulatory and therapeutic properties of FK-565 in mice.

Authors:  J E Talmadge; B Lenz; M Schneider; H Phillips; C Long
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  A novel method for selection of invasive tumor cells: derivation and characterization of highly metastatic K1735 melanoma cell lines based on in vitro and in vivo invasive capacity.

Authors:  T Kalebic; J E Williams; J E Talmadge; C S Kao-Shan; B Kravitz; K Locklear; G P Siegal; L A Liotta; M E Sobel; P S Steeg
Journal:  Clin Exp Metastasis       Date:  1988 Jul-Aug       Impact factor: 5.150

4.  Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid.

Authors:  A E Lee; L A Rogers; J M Longcroft; R E Jeffery
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

5.  Response of natural killer cells from dietary tyrosine- and phenylalanine-restricted mice to biological response modifiers.

Authors:  G G Meadows; R M Abdallah; J R Starkey; C J Aslakson
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.

Authors:  J E Talmadge; M A Chirigos
Journal:  Springer Semin Immunopathol       Date:  1985

7.  Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Authors:  Claudia Maletzki; Yvonne Saara Gladbach; Mohamed Hamed; Georg Fuellen; Marie-Luise Semmler; Jan Stenzel; Michael Linnebacher
Journal:  Oncoimmunology       Date:  2017-12-14       Impact factor: 8.110

8.  A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.

Authors:  Nicholas Butowski; Kathleen R Lamborn; Bee L Lee; Michael D Prados; Timothy Cloughesy; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Frank Lieberman; Minesh Mehta; H Ian Robins; Larry Junck; Andres M Salazar; Susan M Chang
Journal:  J Neurooncol       Date:  2008-10-11       Impact factor: 4.130

9.  Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.

Authors:  M Kende; H W Lupton; W L Rill; P Gibbs; H B Levy; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

10.  Synergism of synthetic acyltripeptide and its analogs with recombinant interferon gamma for activation of antitumor properties of human blood monocytes.

Authors:  S Sone; A Okubo; N Inamura; A Nii; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.